TAROPHEN 36 MG

Valsts: Izraēla

Valoda: angļu

Klimata pārmaiņas: Ministry of Health

Nopērc to tagad

Lejuplādēt Lietošanas instrukcija (PIL)
08-08-2023

Aktīvā sastāvdaļa:

METHYLPHENIDATE HYDROCHLORIDE

Pieejams no:

TARO INTERNATIONAL LTD, ISRAEL

ATĶ kods:

N06BA04

Zāļu forma:

TABLETS EXTENDED RELEASE

Kompozīcija:

METHYLPHENIDATE HYDROCHLORIDE 36 MG

Ievadīšanas:

PER OS

Receptes veids:

Required

Ražojis:

SUN PHARMACEUTICAL INDUSTRIES, INC,USA

Ārstniecības joma:

METHYLPHENIDATE

Ārstēšanas norādes:

Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Autorizācija datums:

2023-05-08

Lietošanas instrukcija

                                Patient leaflet in accordance with the Pharmacists' Regulations
(Preparations) – 1986
This medicine is dispensed with a doctor’s prescription only
Tarophen 18 mg
Tarophen 27 mg
Tarophen 36 mg
Tarophen 54 mg
Extended-release tablets
Active ingredient
Each Tarophen 18 mg tablet contains 18 mg methylphenidate
hydrochloride.
Each Tarophen 27 mg tablet contains 27 mg methylphenidate
hydrochloride.
Each Tarophen 36 mg tablet contains 36 mg methylphenidate
hydrochloride.
Each Tarophen 54 mg tablet contains 54 mg methylphenidate
hydrochloride.
Inactive ingredients and allergens in this medicine: see section 6
‘Additional
information’.
Read the entire leaflet carefully before you start using this
medicine.
This leaflet contains concise information about this medicine. If you
have any
further questions, consult your doctor or pharmacist.
This medicine has been prescribed for you. Do not pass it on to
others. It may
harm them, even if it seems to you that their medical condition is
similar to
yours.
1. What is this medicine intended for?
Tarophen is intended for the treatment of Attention Deficit
Hyperactivity
Disorder (ADHD) in children over the age of 6, adolescents, and adults
up to
the age of 65.
Therapeutic group: central nervous system stimulant.
Tarophen can improve attention and concentration, and reduce
impulsiveness
and hyperactivity in individuals with ADHD. Tarophen should be given
as part
of an ADHD treatment program that may include counseling or other
therapies.
2. Before using this medicine
Do not use this medicine if you or your child:
•
is sensitive (allergic) to the active ingredient (methylphenidate
hydrochloride) or to any of the other ingredients in this medicine
(see
section 6, ‘Additional information’).
•
is very anxious, mentally tense, or agitated (suffers from
restlessness)
•
has an eye problem called glaucoma (increased intraocular pressure)
•
has tics or Tourette's syndrome, or a family history of Tourette's
syndrome. Tics are involuntary repeated movements or sounds.
•
is 
                                
                                Izlasiet visu dokumentu
                                
                            

Dokumenti citās valodās

Lietošanas instrukcija Lietošanas instrukcija arābu 08-08-2023
Lietošanas instrukcija Lietošanas instrukcija ivrits 08-08-2023

Meklēt brīdinājumus, kas saistīti ar šo produktu

Skatīt dokumentu vēsturi